Meningitis c vaccine Health Dictionary

Meningitis C Vaccine: From 1 Different Sources


(MenC) a vaccine that provides protection against the C strain of the bacterium Neisseria meningitidis (the meningococcus), which accounts for approximately 50% of all cases of meningococcal meningitis and tends to occur in clusters. Owing to the success of the MenC vaccination programme begun in 1999 there have been almost no recent cases of meningitis C disease in babies and young children in the UK. The vaccine was previously offered to all babies at 12 weeks of age but is now given at 12 months as part of Hib/MenC vaccine and at 14 years as the MenACWY vaccine.
Health Source: Oxford | Concise Colour Medical Dictionary
Author: Jonathan Law, Elizabeth Martin

Vaccine

A preparation of dead particulate or weakened bacteria or viruses prepared for injection into the body so that antibodies are formed to prevent disease (eg polio). Detoxi fied but genetically potent toxins (called toxoids) can also be used (e.g. tetanus and diphtheria)... vaccine

Meningitis

In?ammation affecting the membranes of the BRAIN or SPINAL CORD, or usually both. Meningitis may be caused by BACTERIA, viruses (see VIRUS), fungi, malignant cells or blood (after SUBARACHNOID HAEMORRHAGE). The term is, however, usually restricted to in?ammation due to a bacterium or virus. Viral meningitis is normally a mild, self-limiting infection of a few days’ duration; it is the most common cause of meningitis but usually results in complete recovery and requires no speci?c treatment. Usually a less serious infection than the bacterial variety, it does, however, rarely cause associated ENCEPHALITIS, which is a potentially dangerous illness. A range of viruses can cause meningitis, including: ENTEROVIRUSES; those causing MUMPS, INFLUENZA and HERPES SIMPLEX; and HIV.

Bacterial meningitis is life-threatening: in the United Kingdom, 5–10 per cent of children who contract the disease may die. Most cases of acute bacterial meningitis in the UK are caused by two bacteria: Neisseria meningitidis (meningococcus), and Streptococcus pneumoniae (pneumococcus); other bacteria include Haemophilus in?uenzae (a common cause until virtually wiped out by immunisation), Escherichia coli, Mycobacterium tuberculosis (see TUBERCULOSIS), Treponema pallidum (see SYPHILIS) and Staphylococci spp. Of the bacterial infections, meningococcal group B is the type that causes a large number of cases in the UK, while group A is less common.

Bacterial meningitis may occur by spread from nearby infected foci such as the nasopharynx, middle ear, mastoid and sinuses (see EAR, DISEASES OF). Direct infection may be the result of penetrating injuries of the skull from accidents or gunshot wounds. Meningitis may also be a complication of neurosurgery despite careful aseptic precautions. Immuno-compromised patients – those with AIDS or on CYTOTOXIC drugs – are vulnerable to infections.

Spread to contacts may occur in schools and similar communities. Many people harbour the meningococcus without developing meningitis. In recent years small clusters of cases, mainly in schoolchildren and young people at college, have occurred in Britain.

Symptoms include malaise accompanied by fever, severe headache, PHOTOPHOBIA, vomiting, irritability, rigors, drowsiness and neurological disturbances. Neck sti?ness and a positive KERNIG’S SIGN appearing within a few hours of infection are key diagnostic signs. Meningococcal and pneumococcal meningitis may co-exist with SEPTICAEMIA, a much more serious condition in terms of death rate or organ damage and which constitutes a grave emergency demanding rapid treatment.

Diagnosis and treatment are urgent and, if bacterial meningitis is suspected, antibiotic treatment should be started even before laboratory con?rmation of the infection. Analysis of the CEREBROSPINAL FLUID (CSF) by means of a LUMBAR PUNCTURE is an essential step in diagnosis, except in patients for whom the test would be dangerous as they have signs of raised intracranial pressure. The CSF is clear or turbid in viral meningitis, turbid or viscous in tuberculous infection and turbulent or purulent when meningococci or staphylococci are the infective agents. Cell counts and biochemical make-up of the CSF are other diagnostic pointers. Serological tests are done to identify possible syphilitic infection, which is now rare in Britain.

Patients with suspected meningitis should be admitted to hospital quickly. General pracitioners are encouraged to give a dose of intramuscular penicillin before sending the child to hospital. Treatment in hospital is usually with a cephalosporin, such as ceftazidime or ceftriaxone. Once the sensitivity of the organism is known as a result of laboratory studies on CSF and blood, this may be changed to penicillin or, in the case of H. in?uenzae, to amoxicillin. Local infections such as SINUSITIS or middle-ear infection require treatment, and appropriate surgery for skull fractures or meningeal tears should be carried out as necessary. Tuberculous meningitis is treated for at least nine months with anti-tuberculous drugs (see TUBERCULOSIS). If bacterial meningitis causes CONVULSIONS, these can be controlled with diazepam (see TRANQUILLISERS; BENZODIAZEPINES) and ANALGESICS will be required for the severe headache.

Coexisting septicaemia may require full intensive care with close attention to intravenous ?uid and electrolyte balance, control of blood clotting and blood pressure.

Treatment of close contacts such as family, school friends, medical and nursing sta? is recommended if the patient has H. in?uenzae or N. meningitidis: RIFAMPICIN provides e?ective prophylaxis. Contacts of patients with pneumococcal infection do not need preventive treatment. Vaccines for meningococcal meningitis may be given to family members in small epidemics and to any contacts who are especially at risk such as infants, the elderly and immuno-compromised individuals.

The outlook for a patient with bacterial meningitis depends upon age – the young and old are vulnerable; speed of onset – sudden onset worsens the prognosis; and how quickly treatment is started – hence the urgency of diagnosis and admission to hospital. Recent research has shown that children who suffer meningitis in their ?rst year of life are ten times more likely to develop moderate or severe disability by the age of ?ve than contemporaries who have not been infected. (See British Medical Journal, 8 September 2001, page 523.)

Prevention One type of bacterial meningitis, that caused by Haemophilus, has been largely controlled by IMMUNISATION; meningococcal C vaccine has largely prevented this type of the disease in the UK. So far, no vaccine against group B has been developed, but research continues. Information on meningitis can be obtained from the Meningitis Trust and the Meningitis Research Foundation.... meningitis

Dpt Vaccine

Often called the TRIPLE VACCINE, the injections produce immunity against DIPHTHERIA, whooping cough (PERTUSSIS) and TETANUS. The vaccine is given as a course of three injections to infants around the ages of two, three and four months, together with haemophilus in?uenza B and meningococcal C vaccine as well as oral polio vaccine. A booster injection is given at school entry (see schedule in IMMUNISATION).... dpt vaccine

Mmr Vaccine

A combined vaccine o?ering protection against MEASLES, MUMPS and RUBELLA (German measles), it was introduced in the UK in 1988 and has now replaced the measles vaccine. The combined vaccine is o?ered to all infants in their second year; health authorities have an obligation to ensure that all children have received the vaccine by school entry – it should be given with the pre-school booster doses against DIPHTHERIA, TETANUS and POLIOMYELITIS, if not earlier – unless there is a valid contra-indication (such as partial immunosuppression), parental refusal, or evidence of previous infection. MMR vaccine may also be used in the control of measles outbreaks, if o?ered to susceptible children within three days of exposure to infection. The vaccine is e?ective and generally safe, though minor symptoms such as malaise, fever and rash may occur 5–10 days after immunisation. The incidence of all three diseases has dropped substantially since MMR was introduced in the UK and USA.

A researcher has suggested a link between the vaccine and AUTISM, but massive studies of children with and without this condition in several countries have failed to ?nd any evidence to back the claim. Nonetheless, the publicity war has been largely lost by the UK health departments so that vaccine rates have dropped to a worryingly low level.

(See IMMUNISATION.)... mmr vaccine

Hib Vaccine

A vaccine administered routinely at 2, 3, and 4 months of age to provide immunity to the bacterium HAEMOPHILUS INFLUENZA type b (Hib).

Before the vaccine was generally available, Hib infection was a common cause of bacterial meningitis and epiglottitis in children.... hib vaccine

Salk Vaccine

A vaccine obtained by treating the POLIOMYELITIS virus with formalin. This prevents the virus from causing the disease but allows it to stimulate the production of ANTIBODIES. Salk vaccine is given by injection and protects the recipient against the disease. (See also IMMUNISATION.)... salk vaccine

Tab Vaccine

A combined VACCINE administered to produce IMMUNITY against typhoid and paratyphoid A and B (see ENTERIC FEVER). (See also IMMUNISATION.)... tab vaccine

Triple Vaccine

Also known as DPT vaccine, this is an injection that provides IMMUNITY against DIPHTHERIA, pertussis (whooping-cough) and TETANUS. It is given as a course of three injections at around the ages of two, three and four months. A booster dose of diphtheria and tetanus is given at primary-school age. Certain infants – those with a family history of EPILEPSY, or who have neurological disorders or who have reacted severely to the ?rst dose – should not have the pertussis element of DPT. (See MMR VACCINE; IMMUNISATION.)... triple vaccine

Bacterial Meningitis

See MENINGITIS.... bacterial meningitis

Bcg Vaccine

BCG (Bacillus Calmette-Guérin) vaccine, which was ?rst introduced in France in 1908, is the only vaccine that has produced signi?cant immunity against the tubercle bacillus (see TUBERCULOSIS) and at the same time has proved safe enough for use in human subjects. BCG vaccination is usually considered for the following groups of people. (1) Schoolchildren: the routine programme in schools usually covers children aged between ten and 14. (2) Students, including those in teacher training colleges. (3) Immigrants from countries with a high prevalence of tuberculosis (TB). (4) Children and newborn infants born in the UK to parents from Group 3, or other newborns at parents’ request. (5) Health workers, such as nurses, and others likely to be exposed to infection in their work. (6) Veterinary workers who handle animals susceptible to TB. (7) Sta? of prisons, residential homes and hostels for refugees and the homeless. (8) Household contacts of people known to have active TB and newborn infants in households where there is a history of the disease. (9) Those staying for more than one month in high-risk countries.

A pre-vaccination tuberculin test is necessary in all age-groups except newborn infants, and only those with negative tuberculin reactions are vaccinated. Complications are few and far between. A local reaction at the site of vaccination usually occurs between two and six weeks after vaccination, beginning as a small papule that slowly increases in size. It may produce a small ulcer. This heals after around two months, leaving a small scar. (See IMMUNITY; TUBERCULIN.)... bcg vaccine

Yellow Fever Vaccine Is Prepared From

chick embryos injected with the living, attenuated strain (17D) of pantropic virus. Only one injection is required, and immunity persists for many years. Re-inoculation, however, is desirable every ten years. (See YELLOW FEVER.)

Haemophilus vaccine (HiB) This vaccine was introduced in the UK in 1994 to deal with the annual incidence of about 1,500 cases and 100 deaths from haemophilus MENINGITIS, SEPTICAEMIA and EPIGLOTTITIS, mostly in pre-school children. It has been remarkably successful when given as part of the primary vaccination programme at two, three and four months of age – reducing the incidence by over 95 per cent. A few cases still occur, either due to other subgroups of the organism for which the vaccine is not designed, or because of inadequate response by the child, possibly related to interference from the newer forms of pertussis vaccine (see above) given at the same time.

Meningococcal C vaccine Used in the UK from 1998, this has dramatically reduced the incidence of meningitis and septicaemia due to this organism. Used as part of the primary programme in early infancy, it does not protect against other types of meningococci.

Varicella vaccine This vaccine, used to protect against varicella (CHICKENPOX) is used in a number of countries including the United States and Japan. It has not been introduced into the UK, largely because of concerns that use in infancy would result in an upsurge in cases in adult life, when the disease may be more severe.

Pneumococcal vaccine The pneumococcus is responsible for severe and sometimes fatal childhood diseases including meningitis and septicaemia, as well as PNEUMONIA and other respiratory infections. Vaccines are available but do not protect against all strains and are reserved for special situations – such as for patients without a SPLEEN or those who are immunode?cient.... yellow fever vaccine is prepared from

Menacwy Vaccine

a vaccine that provides protection against four different strains (A, C, W, and Y) of the bacterium Neisseria meningitidis (the meningococcus) that causes *meningitis and septicaemia. It also prevents the carriage of the bacteria in the nose and back of the throat. In Britain it is offered to children aged 14 years and students going to college and university for the first time.... menacwy vaccine

Meningitis B Vaccine

(MenB) a vaccine that provides protection against the B strain of the bacterium Neisseria meningitidis (the meningococcus), which accounts for more than 90% of meningococcal infections in young children. The MenB vaccine is offered to all babies with their primary *immunizations at 2 and 4 months of age and as a booster at 12 months. See meningitis.... meningitis b vaccine

Sabin Vaccine

Introduced in 1962, the attenuated live oral vaccine (Sabin) against POLIOMYELITIS replaced the previous inactivated vaccine introduced in 1956 (see SALK VACCINE).... sabin vaccine

Nasal Flu Vaccine

(in Britain), a vaccine currently offered to all 2- and 3-year-olds in the form of a spray into each nostril. It contains live forms of the influenza virus that have been attenuated (weakened). The vaccine stimulates the immune system but does not cause disease in healthy people.... nasal flu vaccine

Pneumococcal Vaccine

a vaccine that protects against infection by the bacterium *Streptococcus pneumoniae, which can cause serious diseases, including pneumonia, septicaemia, and *meningitis. Children under 2 years of age and adults over 65 years are at particular risk. Since September 2006, the pneumococcal vaccine has become part of the childhood *immunization programme. It is also offered to people over the age of 65 as a single vaccination that will protect for life.... pneumococcal vaccine

Rotavirus Vaccine

an oral vaccine against *rotavirus infection. In Britain it is offered to babies at 2 and 3 months of age, alongside their other childhood vaccinations.... rotavirus vaccine

 sabin Vaccine

an oral vaccine against (E954) poliomyelitis, prepared by culture of the virus under special conditions so that it loses its virulence (i.e. it becomes attenuated) but retains its ability to stimulate antibody production. [A. B. Sabin (1906–93), US bacteriologist]...  sabin vaccine



Recent Searches